458 related articles for article (PubMed ID: 29429915)
1. CAR T-cells for relapsed B-cell ALL in adults.
Gilbert JA
Lancet Oncol; 2018 Mar; 19(3):e143. PubMed ID: 29429915
[No Abstract] [Full Text] [Related]
2. CAR T-cells for relapsed B-cell ALL in children and young adults.
Stirrups R
Lancet Oncol; 2018 Mar; 19(3):e144. PubMed ID: 29429913
[No Abstract] [Full Text] [Related]
3. Trafficking of CAR T cells to sites of subclinical leukaemia cutis.
O'Reilly M; Roddie C; Marzolini MAV; Rodriguez-Justo M; Pomplun S; Pule M; Peggs KS
Lancet Oncol; 2020 Mar; 21(3):e179. PubMed ID: 32135121
[No Abstract] [Full Text] [Related]
4. Donor origin CAR19 T cell infusion for B-ALL relapsed after allogeneic hematopoietic stem cell transplantation.
Yang X; Dai H; Kang L; Qu C; Li Z; Yin J; Qiu H; Fu C; Han Y; Jin Z; Ma X; Zhu X; Yu L; Wu D; Tang X
Hematol Oncol; 2019 Dec; 37(5):655-658. PubMed ID: 31656047
[No Abstract] [Full Text] [Related]
5. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
Zhang M; Huang H
Front Immunol; 2020; 11():611710. PubMed ID: 33384696
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
Front Immunol; 2018; 9():239. PubMed ID: 29515572
[TBL] [Abstract][Full Text] [Related]
7. Late Events After CD-19 CAR-T Treatment.
Hossain NM; Nishimura MI
Biol Blood Marrow Transplant; 2020 Jan; 26(1):e1-e2. PubMed ID: 31669398
[No Abstract] [Full Text] [Related]
8. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
[TBL] [Abstract][Full Text] [Related]
9. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.
Valecha GK; Ibrahim U; Ghanem S; Asti D; Atallah JP; Terjanian T
Expert Rev Hematol; 2017 Sep; 10(9):783-799. PubMed ID: 28666090
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic.
Bachanova V; Bishop MR; Dahi P; Dholaria B; Grupp SA; Hayes-Lattin B; Janakiram M; Maziarz RT; McGuirk JP; Nastoupil LJ; Oluwole OO; Perales MA; Porter DL; Riedell PA;
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1239-1246. PubMed ID: 32298807
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Pagel JM; West HJ
JAMA Oncol; 2017 Nov; 3(11):1595. PubMed ID: 28880983
[No Abstract] [Full Text] [Related]
12. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
[TBL] [Abstract][Full Text] [Related]
13. Advances in the development of chimeric antigen receptor-T-cell therapy in B-cell acute lymphoblastic leukemia.
Zhang X; Li JJ; Lu PH
Chin Med J (Engl); 2020 Feb; 133(4):474-482. PubMed ID: 31977556
[TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia.
Ceppi F; Gardner RA
Cancer J; 2019; 25(3):191-198. PubMed ID: 31135526
[TBL] [Abstract][Full Text] [Related]
15. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
Luskin MR; DeAngelo DJ
Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
[TBL] [Abstract][Full Text] [Related]
16. Successful Treatment of TCF3-HLF-positive Childhood B-ALL with Chimeric Antigen Receptor T-Cell Therapy.
Wang T; Wan X; Yang F; Shi W; Liu R; Ding L; Tang Y; Luo C; Yang X; Ma Y; Wang X; Liang H; Li B; Lu J; Chen J
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):386-392. PubMed ID: 33640284
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic chimeric antigen receptor T cells for children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Locatelli F; Del Bufalo F; Quintarelli C
Haematologica; 2024 Jun; 109(6):1689-1699. PubMed ID: 38832424
[TBL] [Abstract][Full Text] [Related]
18. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.
Pan J; Yang JF; Deng BP; Zhao XJ; Zhang X; Lin YH; Wu YN; Deng ZL; Zhang YL; Liu SH; Wu T; Lu PH; Lu DP; Chang AH; Tong CR
Leukemia; 2017 Dec; 31(12):2587-2593. PubMed ID: 28490811
[TBL] [Abstract][Full Text] [Related]
19. The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r/r B-ALL patients.
Li M; Xue SL; Tang X; Xu J; Chen S; Han Y; Qiu H; Miao M; Xu N; Tan J; Kang L; Yu Z; Lou X; Xu Y; Chen J; Yan Z; Feng W; Wu D; Yu L
Sci Rep; 2022 Jan; 12(1):378. PubMed ID: 35013456
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Children With Central Nervous System Leukemia.
Zhang L; Zuo Y; Lu A; Wu J; Jia Y; Wang Y; Zhang L
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e410-e414. PubMed ID: 33526401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
